ADSL and urinary tract infection: Schmidt and colleagues showed that AMPs (Onc72 and Onc112) reach several organs within 10 min after intravenous and intraperitoneal administration and the PK experiments explain the high in vivo efficacies of AMPs indicating their potential use for the treatment of urinary tract infections (Schmidt et al., 2016).